Treats infections caused by penicillinase-producing staphylococci. ANDA 91613, held by Eugia Pharma Speclts. Nafcillin Sodium.
As of Nov 16, 2026, ANDA 91613 (Nafcillin Sodium), held by Eugia Pharma Speclts, was first approved by FDA on Dec 26, 2012, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY- Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection, USP should be discontinued and alternative therapy provided.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2012 | Original application | Approved | None posted |
| Nafcillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Nafcillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Feb 11, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 11, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 11, 2018 | Supplement 4Manufacturing | Approved | None posted |
| Dec 26, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters